Myocarditis and Messenger RNA COVID-19 Vaccine: What Is the Risk?

European and American agencies (such as the Centers for Disease Control [CDC]) have begun evaluating reports on myocarditis in individuals who received one of the COVID-19 vaccines based on messenger RNA technology (Pfizer/BioNTech and Moderna).

Miocarditis y vacunas de ARN mensajero

This possible association has not been yet established and, even if confirmed in the future, it would not undermine the enormous benefit provided by vaccines.

The CDC has recently warned the medical community regarding the possible risk of myocarditis when using this type of vaccine.

This alert was issued by the Vaccine Safety Technical Work Group (dedicated exclusively to COVID-19 vaccine safety) based on a few reports of individuals who developed myocarditis after vaccination.

Most cases were in teenagers and young adults (more frequently male), who developed myocarditis within four days from getting the second dose.

Most cases were mild, and follow-up is currently underway to obtain more data on their evolution.


Read also: EuroPCR 2021 | CASTLE: Orsiro vs Xience Guided by Intravascular Imaging.


For now, the myocarditis rate does not differ from that reported in the general population before pandemic. This CDC technical reports is intended to encourage physicians to report all myocarditis events, so that their association with vaccination can be confirmed or ruled out.

The European Medicines Agency safety committee also informed that it was evaluating reports of myocarditis and pericarditis in people who had received either of the two messenger-RNA-based vaccines (mainly the Pfizer/BioNTech vaccine) although, at this time, there is no evidence of any association.

The benefit of vaccination far exceeds the eventual risk of myocarditis—if there actually is such a risk.

Original Title: COVID-19 VaST Work Group Technical Report – May 17, 2021.

Reference: https://www.cdc.gov/vaccines/acip/work-groups-vast/technical-report-2021-05-17.html


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Is the Booster Dose Against COVID-19 Effective for All Ages?

The answer is incontrovertible: it is undeniably effective. For all ages, the confirmed COVID19 and severe case rates were significantly lower for patients who...

Pfizer Booster Dose Efficacy against Omicron

The BNT162b2 vaccine (Pfizer/BioNTech) has previously shown a 95% efficacy against COVID-19. This efficacy has been changing with the surge of new variants and,...

Once Again, the Omicron Variant Tests the Limits of Healthcare Systems, But with Hope

The latest significant COVID-19 variant, the Omicron, is again pushing healthcare systems around the world onto the verge of collapse, having reached over 300...

The Most Read Articles of 2021: COVID-19

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on COVID-19. Follow...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...